Review of neuroendocrine disturbances in the chronic fatigue syndrome: Indications for a role of the growth hormone-IGF-1 axis in the pathogenesis

Journal of Chronic Fatigue Syndrome

Volumn 4, Issue 4, 1998, Pages 81-91

  Berwaerts, Joris ^a,b,c   Moorkens, Greta ^a   Abs, Roger ^a  

^a ANTWERP UNIVERSITY HOSPITAL   (Belgium)

^b MIDDELHEIM HOSPITAL   (Belgium)

^c UNIVERSITY OF ABERDEEN   (United Kingdom)

Author keywords

Chronic fatigue syndrome; GH IGF 1; Glucocorticoid; PRL; Serotonin

Indexed keywords

SOMATOMEDIN BINDING PROTEIN 1;

CHRONIC FATIGUE SYNDROME; CLINICAL FEATURE; DISEASE COURSE; GROWTH HORMONE RELEASE; HYPOTHALAMUS HYPOPHYSIS ADRENAL SYSTEM; NEUROENDOCRINE DISEASE; PATHOGENESIS; REVIEW; SEROTONINERGIC SYSTEM;

EID: 0032466579     PISSN: 10573321     EISSN: None     Source Type: Journal    
DOI: 10.1300/J092v04n04_07     Document Type: Review

References (55)

1. Beam J, Allain T, Coskeran P, et al. Neuroendocrine responses to d-fenfluramine and insulin-induced hypoglycemia in chronic fatigue syndrome. Biol Psychiatry 1995; 37: 245-52.
2. Sharpe M, Clements A, Hawton K, et al. Increased prolactin response to buspirone in chronic fatigue syndrome. J Affect Disord 1996; 41: 71-6.
3. Cleare AJ, Beam J, Allain T, et al. Contrasting neuroendocrine responses in depression and chronic fatigue syndrome. J Affect Disord 1995; 35: 283-9.
4. Bakheit AMO, Behan PO, Dinan TG, et al. Possible upregulation of hypothalamic 5-hydroxytryptamine receptors in patients with postviral fatigue syndrome. Br Med J 1992; 304: 1010-2.
5. Demitrack MA, Dale JK, Straus SE, et al. Evidence for impaired activation of the hypothalamic-pituitary-adrenal axis in patients with chronic fatigue syndrome. J Clin Endocrinol Metab 1991; 73: 1224-34.
6. Bennett RM, Clark SR, Campbell SM, et al. Low levels of somatomedin C in patients with the fibromyalgia syndrome: a possible link between sleep and muscle pain. Arthritis Rheum 1992; 35: 1113-6.
7. Allain TJ, Beam JA, Coskeran P, et al. Changes in growth hormone, insulin, insulin-like growth factors (IGFs), and IGF-binding protein-1 in chronic fatigue syndrome. Biol Psychiatry 1997; 41: 567-73.
8. Majeed T, Dinan TG, Thakore J, et al. Defective dexamethasone induced growth hormone release in chronic fatigue syndrome: evidence for glucocorticoid receptor resistance and lack of plasticity? J Ir Coll Phys Surg 1995; 24: 20-4.
9. Buchwald D, Umali J, Stene M. Insulin-like growth factor-I (somatomedin C) levels in chronic fatigue syndrome and fibromyalgia. J Rheumatol 1996; 23: 739-42.
10. Demitrack MA, Gold PW, Dale JK, et al. Plasma and cerebrospinal fluid monoamine metabolism in patients with chronic fatigue syndrome: preliminary findings. Biol Psychiatry 1992; 32: 1065-77.
11. Blomstrand E, Perrett D, Parry-Billings M, et al. Effect of sustained exercise on plasma amino acid concentrations and on 5-hydroxytryptamine metabolism in six different brain regions in the rat. Acta Physiol Scand 1989; 136: 473-81.
12. Baily SP, Davis JM, Ahlborn EN. Neuroendocrine and substrate responses to altered brain 5-HT activity during prolonged exercise to fatigue. J Appl Physiol 1993; 74: 3006-12.
13. Berwaerts J, Moorkens G, Abs R. Secretion of growth hormone in patients with chronic fatigue syndrome. Growth Regulation (in press).
14. Korbonits M, Besser M. Diagnosis of growth hormone deficiency in adults. Horm Res 1996; 46: 174-82.
15. Dinan TG. Serotonin and the regulation of hypothalamic-pituitary-adrenal axis function. Life Sci 1996; 58: 1683-94.
16. Yehuda R, Meyer JS. A role for serotonin in the hypothalamic-pituitary-adrenal response to insulin stress. Neuroendocrinology 1984; 38: 25-32.
17. Prescott RWG, Kendall-Taylor P, Weightman DR, et al. The effect of ketanserin, a specific serotonin antagonist, on the PRL, GH. ACTH and Cortisol responses to hypoglycemia in normal subjects. Clin Endocrinol (Oxf) 1984; 20: 137-42.
18. TepavceviL D, GiljeviL Z, AganoviL I, et al. Effects of ritanserin, a specific serotonin-S2 receptor antagonist, on the release of anterior pituitary hormones during insulin-induced hypoglycemia in normal humans. J Endocrinol Invest 1995; 18: 427-30.
19. Lesch KP, Söhnle K, Poten B, et al. Corticotropin and cortisol secretion after central 5-hydroxytryptamine-1A (5-HT1A) receptor activation: effects of 5-HT receptor and beta-adrenoceptor antagonists. J Clin Endocrinol Metab 1990; 70: 670-4.
20. Cowen PJ, Anderson IM, Grahame-Smith DG. Neuroendocrine effects of azapirones. J Clin Psychopharmacol 1990; 10: 21S-25S.
21. Silverstone PH, Rue JE, Franklin M, et al. The effects of administration of mCPP on psychological, cognitive, cardiovascular, hormonal and MHPG measurements in human volunteers. Int Clin Psychopharmacol 1994; 9: 173-8.
22. Katakami H, Arimura A, Frohman LA. Involvement of hypothalamic somatostatin in the suppression of growth hormone secretion by central corticotropin-releasing factor in conscious male rats. Neuroendocrinology 1985; 41: 390-3.
23. Barbarino A, Corsello SM, Della Casa S, et al. Corticotropin-releasing hormone inhibition of growth hormone-releasing hormone-induced growth hormone release in man. J Clin Endocrinol Metab 1990; 71: 1368-74.
24. Thakore JH, Dinan TG. Growth hormone secretion: the role of glucocorticoids. Life Sci 1994; 55: 1083-99.
25. Smals AE, Pieters GF, Smals AG, et al. Human pancreatic growth hormone-releasing hormone fails to stimulate human growth hormone both in Cushing's disease and in Cushing's syndrome due to adrenocortical adenoma. Clin Endocrinol (Oxf) 1986; 24: 401-7.
26. Giustina A, Romanelli G, Candrina R, et al. Growth hormone deficiency in patients with idiopathic adrenocorticotropin deficiency resolves during glucocorticoid replacement. J Clin Endocrinol Metab 1989; 68: 120-4.
27. Kuhn CM, Schanberg SM. Maturation of central nervous system control of growth hormone secretion in rats. J Pharmacol Exp Ther 1981; 217: 152-6.
28. Willoughby JO, Menadue MF, Liebelt H. Activation of serotonin receptors in the medial basal hypothalamus stimulates growth hormone secretion in the unanesthetized rat. Bain Res 1987; 404: 319-22.
29. Yamauchi K, Murakami Y, Koshimura K, et al. Involvement of pituitary adenylate cyclase-activating polypeptide in growth hormone secretion induced by serotoninergic mechanisms in the rat. Endocrinology 1996; 137: 1693-7.
30. López F, Gónzalez D, Aguilar E. Serotonin stimulates GH secretion through a direct pituitary action: studies in hypophysectomized autografted animals and in perfused pituitaries. Acta Endocrinol (Copenh) 1986; 113: 317-22.
31. Conway S, Richardson L, Speciale S, et al. Interaction between norepinephrine and serotonin in the neuroendocrine control of growth hormone release in rats. Endocrinology 1990; 126: 1022-30.
32. Aulakh CS, Hill JL, Lesch KP, et al. Functional subsensitivity of 5-hydroxytryptamine1C or alpha 2 adrenergic heteroreceptors mediating clonidine-induced growth hormone release in the Fawn-Hooded rat strain relative to the Wistar rat strain. J Pharmacol Exp Ther 1992; 262: 1038-43.
33. Munoz-Acedo G, Arilla E. Modulation by 5-hydroxytryptamine of the somatostatin receptor-effector system and somatostatin levels in rat brain. Brain Res Mol Brain Res 1996; 37: 259-66.
34. Anderson IM, Cowen PJ. Effect of pindolol on endocrine and temperature responses to buspirone in healthy volunteers. Psychopharmacology (Berl) 1992; 106: 428-32.
35. Boeles S, Williams C, Campling GM, et al. Sumatriptan decreases food intake and increases plasma growth hormone in healthy women. Psychopharmacology (Berl) 1997; 129: 179-82.
36. Chrousos GP, Gold PW. The concepts of stress and stress system disorders: overview of physical and behavioral homeostasis. JAMA 1992; 267: 1244-52.
37. Cleare AJ, Wessely SC. Chronic fatigue syndrome: a stress disorder? Br J Hosp Med 1996; 55: 571-4.
38. Wood GC, Bentall RP, Gopfert M, et al. The differential response of chronic fatigue, neurotic an muscular dystrophy patients to experimental psychological stress. Psychol Med 1994; 24: 357-64.
39. Crofford LJ, Demitrack MA. Evidence that abnormalities of central neurohormonal systems are key to understanding fibromyalgia and chronic fatigue syndrome. Rheum Dis Clin North Am 1996; 22: 267-84.
40. Straus SE, Dale JK, Wright R, et al. Allergy and the chronic fatigue syndrome. J Allergy Clin Immunol 1988; 81, 791-5.
41. De Kloet ER, Kovács GL, Szabó G, et al. Decreased serotonin turnover in the dorsal hippocampus of rat brain shortly after adrenalectomy: selective normalization after corticosterone substitution. Brain Res 1982; 239: 659-63.
42. De Kloet ER, Sybesma H, Reul HM. Selective control by corticosterone of serotoninl receptor capacity in raphe-hippocampal system. Neuroendocrinology 1986; 42: 513-21.
43. Dinan TG. Noradrenergic and serotoninergic abnormalities in depression: stress-induced dysfunction? J Clin Psychiatry 1996; 57 Suppl 4: 14-8.
44. Thakore JH, Dinan TG. Cortisol synthesis inhibition: a new treatment strategy for the clinical and endocrine manifestations of depression. Biol Psychiatry 1995; 37: 364-8.
45. Scott LV, Dinan TG. The neuroendocrinology of chronic fatigue syndrome. Journal of Chronic Fatigue Syndrome 1996; 2(4): 49-59.
46. Delitala G, Tomasi P, Virdis R. Prolactin, growth hormone and thyrotropinthyroid hormone secretion during stress states in man. Baillieres Clin Endocrinol Metab 1987; 1: 391-414.
47. Cocchi D, Di Giulio A, Groppetti A, et al. Effect of hypophysectomy and growth hormone on tryptophan and serotonin metabolism. Acta Vitaminol Enzymol 1975; 29: 90-6.
48. Popova J, Ivanova E, Tosheva T, et al. Growth hormone and somatostatin treatment change 5-HT1 receptor activity. Gen Pharmacol 1991; 22: 1143-6.
49. de la Fuente JR, Wells LA. Human growth hormone in psychiatric disorders. J Clin Psychiatry 1981; 42: 270-4.
50. Moldofsky H, Scarisbrick P, England R, et al. Musculoskeletal symptoms and non-REM sleep disturbance in patients with "fibrositis syndrome" and healthy subjects. Psychosom Med 1975; 37: 341-51.
51. Morriss R, Sharpe M, Sharpley AL, et al. Abnormalities of sleep in patients with the chronic fatigue syndrome. Br Med J 1993; 306: 1161-3.
52. Fischler B, Le Bon O, Hoffmann G, et al. Sleep abnormalities in the chronic fatigue syndrome. A comorbidity study, Neuropsychobiology 1997; 35: 115-22.
53. Van Cauter E, Plat L. Physiology of growth hormone secretion during sleep. J Pediatr 1996; 128: S32-7.
54. Mendelson WB. Studies of human growth hormone secretion in sleep and waking. Int Rev Neurobiol 1982; 23: 367-89.
55. Moorkens G, Wynants H, Abs R. The effect of somatotropin (rGH) administration in patients with chronic fatigue syndrome (CFS), Growth Regulation (in press).